Free Trial
→ Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ALZN

Alzamend Neuro 9/13/2023 Earnings Report

Alzamend Neuro logo
$2.41 +0.01 (+0.42%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$2.39 -0.02 (-0.83%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Alzamend Neuro EPS Results

Actual EPS
-$54.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Alzamend Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alzamend Neuro Announcement Details

Quarter
Date
9/13/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Alzamend Neuro Earnings Headlines

Alzamend Neuro (ALZN) Expected to Announce Earnings on Wednesday
September 3, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30309377
Alzamend Neuro Increases Common Stock Through Conversion
August 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alzamend-neuro-increases-common-stock-through-conversion?utm_source=marketbeat.com&utm_medium=referral
REVEALED: Something Big Happening Behind White House Doors
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
 |  Paradigm Press (Ad)
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
July 28, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/28/3122431/0/en/alzamend-neuro-to-present-at-the-2025-military-health-system-research-symposium.html
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
July 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/23/3120190/0/en/alzamend-neuro-reports-annual-2025-financial-results-and-provides-update-on-clinical-programs.html
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
June 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/16/3099775/0/en/alzamend-neuro-announces-final-closing-of-5-million-private-placement-months-ahead-of-schedule.html
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles